Provided by Sibel Yilmaz
Sibel Yilmaz advises on all aspects of competition law, foreign investment and foreign subsidies screening, with a focus on the life sciences, technology and private equity sectors.
Sibel has particular expertise in the life sciences sector and has been involved in some of the industry's most high profile matters in recent years, including representing Novartis on its $30 billion acquisition of GSK’s oncology business, advising Takeda on its sale of certain respiratory products to AstraZeneca and representing clients in several investigations relating to alleged excessive prices and other non-competitive practices in the life science sector.
Provided by Chambers
Provided by Chambers
